Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics Inc. director Mark Fishman received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and were awarded as compensation, not purchased in the open market.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, as long as Fishman continues serving on the board through that date. The options expire on June 3, 2036, giving him long-term potential ownership if exercised.
Beam Therapeutics Inc. director Guindo Chirfi received a stock option grant as equity compensation. The award covers 19,676 shares of Beam common stock at an exercise price of $29.55 per share, expiring on June 3, 2036. The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual meeting of stockholders, as long as Chirfi continues serving on the board through the vesting date. This is a non-cash, routine director compensation grant and not an open-market share purchase or sale.
Beam Therapeutics Inc. director Graham K. Cooper reported receiving a grant of stock options to acquire 19,676 shares of common stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, provided he continues serving on the board through the vesting date. Following this grant, he holds 19,676 derivative securities directly.
Beam Therapeutics Inc. reports Q1 2026 results with license and collaboration revenue of $31.7 million, up from $7.5 million a year earlier, narrowing operating loss. Research and development spending reached $104.5 million, while net loss improved to $94.3 million, or $0.91 per share.
Beam ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities and drew an initial $100 million from a new credit facility maturing in 2033. Management believes this liquidity can fund operations for at least 12 months as the company advances multiple base-editing programs, including risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency.
Beam Therapeutics reported first quarter 2026 results alongside major clinical milestones. License and collaboration revenue rose to $31.7 million, up from $7.5 million a year earlier, while net loss narrowed to $94.3 million or $0.91 per share. Cash, cash equivalents and marketable securities totaled $1.2 billion as of March 31, 2026, supporting a projected cash runway into mid-2029.
Clinically, updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency showed rapid, durable increases in total and functional AAT and a well‑tolerated safety profile, leading Beam to select 60 mg as the optimal biological dose and plan a pivotal expansion cohort in the second half of 2026 under an accelerated approval pathway. In sickle cell disease, Phase 1/2 BEACON data for risto-cel were published in The New England Journal of Medicine, and Beam expects to submit a biologics license application as early as year‑end 2026.
Beam also plans an IND filing for BEAM-304 in phenylketonuria and initial 2026 data for BEAM-301 in glycogen storage disease type Ia, while an ongoing healthy volunteer trial of BEAM-103 is expected to complete dosing in the first half of 2026.
Beam Therapeutics ownership filing shows Vanguard Capital Management reports beneficial ownership of 5,122,475 shares of common stock, representing 5.02% of the class. The filing states sole voting power for 745,101 shares and sole dispositive power for 5,122,475 shares; the report is dated 04/29/2026.
The disclosure notes holdings include securities held for various Vanguard affiliates and funds and follows SEC Release No. 34-39538 guidance on aggregated business-unit reporting.
Beam Therapeutics is asking stockholders to vote at a fully virtual 2026 annual meeting on June 3, 2026. The agenda includes electing three Class III directors (John Evans, John Maraganore, Ph.D., and Christi Shaw), ratifying Deloitte & Touche LLP as auditor for 2026, and approving NEO pay on an advisory basis.
Stockholders of record at the close of business on April 7, 2026, when 102,745,693 common shares were outstanding, may vote online, by phone, mail, or during the webcast. The proxy details board structure, independence, risk oversight, and an executive pay program focused on performance-based cash bonuses and equity awards. In 2025, CEO John Evans received total compensation of $5.8 million, with bonuses funded at 135% of target after positive clinical, financing, and pipeline milestones.
Beam Therapeutics Inc. CEO John M. Evans reported an automatic sale of 30,078 shares of common stock on April 1, 2026 at $24.58 per share. According to the disclosure, these shares were sold in a non-discretionary transaction solely to cover tax withholding obligations tied to previously granted restricted stock units under the company’s 2019 Equity Incentive Plan, pursuant to a Rule 10b5-1 trading plan adopted in May 2023. Following this transaction, Evans directly holds 1,047,205 shares and indirectly holds 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, which total includes 616 shares acquired under the company’s amended and restated 2019 Employee Stock Purchase Plan on March 31, 2026.